The House Concurrent Resolution establishes the PACE Task Force in Louisiana to prioritize access, care, and education regarding GLP-1 medications, which have become significant treatments for Type 2 diabetes and chronic weight management. The task force will study the clinical history, accessibility, and insurance costs associated with these medications, which have seen a dramatic increase in demand and pricing, leading to substantial financial strain on state-sponsored insurance plans. The resolution highlights the need for a comprehensive evaluation of GLP-1 utilization and actuarial dynamics to develop sustainable solutions that expand healthcare access while maintaining the fiscal health of the state.

The PACE Task Force will consist of various stakeholders, including representatives from the Louisiana Department of Insurance, the Louisiana Association of Health Plans, and healthcare providers specializing in endocrinology and obesity. The task force is tasked with examining several critical issues, such as pricing disparities for diabetes versus weight loss indications, the impact of strict approval policies on insurer spending, and the accessibility of GLP-1 medications for lower-income or uninsured populations. The task force is required to submit a written report of its findings and recommendations to the legislature by February 12, 2027, and will be dissolved upon completion of its work or by that date, whichever comes first.